Beiersdorf, the global skincare company behind brands like NIVEA, has announced a new partnership and investment in Vincere Biosciences, a biotech company focused on cellular health. Together, they plan to develop advanced skincare products that target skin aging by improving mitochondrial function—a process known as mitophagy.
Mitophagy is the body’s way of clearing out damaged mitochondria, the “powerhouses” of cells. Healthy mitochondria are vital for youthful, glowing skin. By enhancing this natural process, the partnership aims to create cosmetic products that improve skin vitality and reduce visible signs of aging.
Beiersdorf brings decades of experience with coenzyme Q10, a well-known antioxidant that supports mitochondrial health. Vincere contributes cutting-edge research on USP30, an enzyme that plays a key role in mitophagy. Vincere’s work in this area was originally focused on treatments for neurodegenerative diseases, but the collaboration opens the door to applying this science in skincare for the first time.
“This partnership allows us to combine powerful science with deep skincare knowledge,” said representatives from Beiersdorf. “It’s a step forward in turning complex cellular processes into real anti-aging solutions.”
As more consumers look for evidence-based and high-performance beauty products, Beiersdorf’s move reflects its commitment to stay ahead of innovation in the cosmetics industry. By working with a biotech company, it bridges the gap between pharmaceutical science and personal care, aiming to deliver products that support skin health at a cellular level.
This partnership also supports Beiersdorf’s long-term goal to better understand skin biology and develop next-generation ingredient technologies for its global brands.
Related topics:
